Intellia Therapeutics Completes HAELO Study Phase III Recruitment

Summary

Intellia Therapeutics Inc. has completed enrollment in the global Phase 3 HAELO study of Lonvoguran Ziclumeran (LONVO-Z) for hereditary angioedema. Topline data is expected in the first half of 2026, with a BLA submission planned for the second half of 2026 and an anticipated U.S. launch in the first half of 2027. Additional data from the Phase 1/2 study will be presented in Q4 of 2025.Reuters

Impact Analysis

So basically, Intellia Therapeutics has hit a major milestone by completing enrollment for its Phase 3 HAELO study of LONVO-Z for hereditary angioedema. This is a crucial step towards commercialization, with topline data expected in the first half of 2026 and a potential U.S. launch in early 2027.Reuters The interesting part isn’t just the completion of enrollment but the timing and the clear roadmap they’ve laid out. This shows strong execution and confidence from management. Given the recent volatility in their stock, dropping from over $30 to around $11.36, this news could be a catalyst for a rebound, especially with significant investments from ARK Invest and other major players.Invezz+ 3 The market might be underestimating the long-term potential here, particularly with the upcoming data presentations and the strategic focus on rare diseases. Watch for sentiment shifts and potential upside as we get closer to the data readouts and BLA submission.